Search KLH Site
Find Articles by Tags
Addiction (18) Adjuvant - Alum (1) Adjuvant - GPI-0100 (1) Adjuvant - IL-4 (9) Adjuvant GM-CSF (16) Adjuvant KLH (4) Adjuvant Oil / Surfactant (4) Adjuvant QS-21 (25) Age & Physical Activity (3) Allergen-specific immunotherapy (1) Allergy – Pollen (2) Alzheimer's Disease (3) Antibody Response (35) Antibody Response IgA (14) Antibody Response IgE (6) Antibody Response IgG (106) Antibody Response IgM (71) Antibody Response IgY (1) APEC (1) Assay - Bioassay (2) Assay - Carbohydrate Microarray (1) Assay - ELISA (55) Assay - ELISPOT (7) Assay - Immunoassay (8) Assay - InVitro (18) Assay - InVivo (1) Atopic Dermatitis (1) Autoimmune Disease (1) B-epitope (1) Bone Marrow Transplant (6) Cancer (6) Cancer - Bladder (16) Cancer - Brain & CNS (8) Cancer - Breast (15) Cancer - Cervical (1) Cancer - Colorectal (10) Cancer - Esophageal (1) Cancer - Female Reproductive (7) Cancer - Leukemia (2) Cancer - Lung (4) Cancer - Lymphoma (25) Cancer - Melanoma (37) Cancer - Mesothelioma (1) Cancer - Myeloma (15) Cancer - Other (2) Cancer - Ovarian (3) Cancer - Pancreas (1) Cancer - Pediatric (3) Cancer - Peritoneal (2) Cancer - Prostate (9) Cancer - Renal (13) Cancer - Sarcoma (2) Clostridium difficile (5) Crohn's Disease (2) Cross-Reactive Antigens (6) Delayed-type hypersensitivity response (1) Dendritic Cell (66) Developmental (10) Diabetes (2) Disease Resistence (1) DNP-Ficoll (2) DTH (67) Environmental (15) Escherichia coli (1) Fingolimod (Gilenya) (1) Healthy Volunteers (18) HealthyAntibody Response - IgA (1) Hepatitis (2) HIV (11) HPV (3) Husbandry (3) Hypertension (1) id-KLH (29) IL 1 (4) IL 12 (2) IL 15 (1) IL 2 (10) IL 5 (1) IL 6 (1) IL 7 (1) Immune Disease - Autoimmune (13) Immune Disease - Primary (2) Immune Disease – Secondary (1) Immune Response - Cellular (187) Immune Response - Humoral (259) Immune Response Humoral (2) Immunotoxicity (37) Infection (1) Infectious Disease (5) Inflammatory Disease (1) Intradermal KLH (1) Kidney (1) KLH-BEC2 (1) KLH-BP16 (1) KLH-BPO (1) KLH-Conjugate (69) KLH-EGFR (2) KLH-FITC (1) KLH-Ganglioside (16) KLH-Globo H (7) KLH-GM2 (1) KLH-hD1 (1) KLH-HGP-30 (1) KLH-IL (1) KLH-Kinoid (8) KLH-Lewis Y (3) KLH-MUC (8) KLH-Oxycodone (2) KLH-sTn (9) KLH-TF (5) KLH-TN (3) Model - Canine (6) Model - Guinea Pig (10) Model - Livestock (10) Model - Mouse (73) Model - Other (32) Model - Primate (12) Model - Rat (51) Multiple Sclerosis (1) Nasal (3) Natrural Antibody (1) Neonatal (2) NK Cells (1) NSAID (1) Oral KLH (9) Oxycodone (3) Parasitic Disease (6) Pediatric (1) Plant-made (2) PLNA (1) Population Density (3) Psoriasis (1) Review Article (2) Rheumatoid Arthritis (11) Rituximab (Rituxan) (4) Russian thistle (1) Sal k 1 (1) Stress (8) Systemic Lupus Erythematosus (SLE) (7) TACA (2) TDAR (127) Therapeutics - KLH Alone (15) Transplant (6) Ultra Violet radiation (1) Uveitis (1) VEGF (3) Veterinary (1)
Terms and Privacy

KLH in Publications

Publications of scientific research involving KLH. Abstracts or full text articles are available by link to outside sites. If you know of a KLH-related publication that is not yet on KLH Site™, let us know.

(in order by date)

Entries in Cancer - Lymphoma (25)


Clinical Safety and Immunogenicity of Tumor-Targeted, Plant-Made Id-KLH Conjugate Vaccines for Follicular Lymphoma

Daniel Tusé, Nora Ku, Maurizio Bendandi, Carlos Becerra, Robert Collins Jr., Nyla Langford, Susana Inogés Sancho, Ascensión López-Díaz de Cerio, Fernando Pastor, Romy Kandzia, Frank Thieme, Franziska Jarczowski, Dieter Krause, Julian K.-C. Ma, Shan Pandya, Victor Klimyuk, Yuri Gleba, and John E. Butler-Ransohoff.

BioMed Research InternationalVolume 2015 (2015), Article ID 648143


Lymphoma Immunotherapy: Current Status

Roberta Zappasodi, Filippo de Braud, and Massimo Di Nicola.

Front Immunol. 2015; 6: 448
Published online 2015 Sep 1. doi: 10.3389/fimmu.2015.00448 


Lymphoma Vaccine Therapy: Next Steps After a Positive, Controlled Phase III Clinical Trial


Idiotype immunization following high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma.

Holman PR, Costello C, deMagalhaes-Silverman M, Corringham S, Castro J, Ball ED.

Biol Blood Marrow Transplant. 2012 Feb;18(2):257-64. Epub 2011 Jul 4


Cancer Immunotherapy: Sipuleucel-T and Beyond

Aimee E. Hammerstrom, Pharm.D., Diana H. Cauley, Pharm.D., Bradley J. Atkinson, Pharm.D., and Padmanee Sharma, M.D., Ph.D.

Pharmacotherapy. Author manuscript; available in PMC 2014 Sep 10.




Phase I Study of Ipilimumab (MDX-010), an anti-CTLA-4 monoclonal antibody, in patients with Relapsed and Refractory B-cell non-Hodgkin Lymphoma

Stephen M. Ansell, Sara A. Hurvitz, Patricia A. Koenig, Betsy R. LaPlant, Brian F. Kabat, Donna Fernando, Thomas M. Habermann, David J. Inwards, Meena Verma, Reiko Yamada, Charles Erlichman, Israel Lowy, and John M. Timmerman

Clin Cancer Res. 2009 October 15; 15(20): 6446–6453.


Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma.

Freedman A, Neelapu SS, Nichols C, Robertson MJ, Djulbegovic B, Winter JN, Bender JF, Gold DP, Ghalie RG, Stewart ME, Esquibel V, Hamlin P.

J Clin Oncol. 2009 Jun 20;27(18):3036-43. Epub 2009 May 4.


Enhanced immune stimulation by a therapeutic lymphoma tumor antigen vaccine produced in insect cells involves mannose receptor targeting to antigen presenting cells

David J. Betting, Xi Y. Mu, Kamran Kafi, Desmond McDonnel, Francisco Rosas, Daniel P. Gold, and John M. Timmerman. 

Vaccine. 2009 January 7; 27(2): 250–259


Prolonged idiotypic vaccination against follicular lymphoma

Inoges S, Lopez-Diaz de Cerio A, Zabalegui N, Soria E, Villanueva H, Panizo C, Rodriguez-Caballero A, Suarez L, Pastor F, Rodriguez-Calvillo M, Orfao A, Bendandi M.

Leuk Lymphoma. 2009 Jan;50(1):47-53


Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma

John M. Timmerman, Julie M. Vose, Debra K. Czerwinski, Wen-Kai Weng, Diane Ingolia, Martha Mayo, Dan W. Denney, and Ronald Levy.  

Leuk Lymphoma. 2009 January; 50(1): 37–46.


Maleimide conjugation markedly enhances the immunogenicity of both human and murine idiotype-KLH vaccines

Kamran Kafi, David J. Betting, Reiko E. Yamada, Michael Bacica, Kristopher K. Steward, and John M. Timmerman. 

Mol Immunol. 2009 January; 46(3): 448–456


Developing idiotype vaccines for lymphoma: From preclinical studies to Phase III clinical trials

Hyun Jun Park and Sattva S. Neelapu, M.D.  

Br J Haematol. 2008 June; 142(2): 179–191


Vaccine strategies in the treatment of low-grade non-Hodgkin lymphoma.

Koumarianou A, Kountourakis P, Economopoulos T.

J Steroid Biochem Mol Biol. 2008 Apr;109(3-5):230-2. Epub 2008 Mar 7.


Dendritic cells loaded with apoptotic antibody-coated tumor cells provide protective immunity against B-cell lymphoma in vivo

Suzanne N. Franki, Kristopher K. Steward, David J. Betting, Kamran Kafi, Reiko E. Yamada, and John M. Timmerman.

Blood. 2008 February 1; 111(3): 1504–1511.


Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: Safety and immunogenicity in a phase I clinical study

A. McCormick, S. Reddy, S. J. Reinl, T. I. Cameron, D. K. Czerwinkski, F. Vojdani, K. M. Hanley, S. J. Garger, E. L. White, J. Novak, J. Barrett, R. B. Holtz, D. Tusé, R. Levy.

PNAS Current Issue, vol 105, no 29, doi: 10.1073/pnas.0803636105




BiovaxID: a personalized therapeutic cancer vaccine for non-Hodgkin's lymphoma.

Lee ST, Jiang YF, Park KU, Woo AF, Neelapu SS.

Expert Opin Biol Ther. 2007 Jan;7(1):113-22.


Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses.

Redfern CH, Guthrie TH, Bessudo A, Densmore JJ, Holman PR, Janakiraman N, Leonard JP, Levy RL, Just RG, Smith MR, Rosenfelt FP, Wiernik PH, Carter WD, Gold DP, Melink TJ, Gutheil JC, Bender JF.

J Clin Oncol. 2006 Jul 1;24(19):3107-12. Epub 2006 Jun 5.

Full text


Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin's lymphomas: a focus on FavId.


Rituximab treatment results in impaired secondary humoral immune responsiveness

Lizet E. van der Kolk, Joke W. Baars, Martin H. Prins, Marinus H. J. van Oers

Blood September 15,2002 vol. 100 no. 6 2257-2259


Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients.

Timmerman JM, Czerwinski DK, Davis TA, Hsu FJ, Benike C, Hao ZM, Taidi B, Rajapaksa R, Caspar CB, Okada CY, van Beckhoven A, Liles TM, Engleman EG,Levy R.

Blood. 2002 Mar 1;99(5):1517-26.